Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials.
about
Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients.Pediatric Glaucoma: Pharmacotherapeutic Options.Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionEvaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% - an observational switch study.Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications.
P2860
Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Bimatoprost 0.01% or 0.03% in ...... two randomized 12-week trials.
@en
type
label
Bimatoprost 0.01% or 0.03% in ...... two randomized 12-week trials.
@en
prefLabel
Bimatoprost 0.01% or 0.03% in ...... two randomized 12-week trials.
@en
P2093
P2860
P356
P1476
Bimatoprost 0.01% or 0.03% in ...... two randomized 12-week trials.
@en
P2093
David A Hollander
Fiaz Zaman
Jonathan S Myers
Julia M Williams
Steven Vold
P2860
P304
P356
10.2147/OPTH.S59197
P407
P577
2014-03-27T00:00:00Z